Pfizer conducts late-stage clinical trials to compete in GLP-1 weight loss market
PFE Pfizer Inc
$29.23 -0.54%
View chart & analysis → - 1Pfizer acquired a new GLP-1 drug under development.
- 2Pfizer holds 10 late-stage clinical trials in its weight loss portfolio.
- 3Pfizer's GLP-1 drug shows a 12% weight reduction even after switching to monthly dosing.
So what's the key point?
Pfizer has introduced a new drug to help with weight loss. The drug is competitive because it can reduce weight by 12% with just one dose per month.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.